We have previously shown that lung tumors arising in MMTV-IGF-II transgenic mice displayed elevated levels of phosphorylated cAMP response element binding protein (CREB). To investigate the role that insulin-like growth factor II (IGF-II) and CREB play in human lung tumorigenesis, A549 and NCI-H358 cells were examined. In these cell lines, IGF-II administration enhances human tumor cell survival and CREB phosphorylation. Further, the effects of IGF-II on cell survival and CREB phosphorylation appeared to be mediated, at least in part, by activation of the Erk pathways, as inhibition of these signaling pathways reduced tumor cell survival and CREB phosphorylation. Specifically, Erk5 appeared as the predominant mediator of CREB phosporylation. To further verify the importance of CREB in human lung tumorigenesis, A549 and NCI-H358 cells were stably transfected with a vector containing a dominant negative CREB construct (KCREB). KCREB transfection significantly inhibited the soft agar growth of both human tumor cell lines. In contrast, overexpression of wild-type CREB in the normal human bronchial epithelial cell line, HBE135, enhanced soft agar growth. Therefore, our results indicate that CREB and its associated proteins play a significant role in lung adenocarcinoma and IGF-II induces CREB phosphorylation, at least in part, via the Erk5 signaling pathway.
Introduction
The insulin-like growth factor (IGF) family, consisting of insulin-like growth factor I and II (IGF-I and IGF-II), their receptors IGF-I receptor and IGF-II receptor (IGF-IR and IGF-IIR) and six IGF binding proteins (IGFBPs1-6), plays a critical role in normal growth and differentiation of many tissues. In the lung, IGF-II has an important role during fetal development, whereas IGF-I is the major regulator of postnatal growth in normal lung cells (Fowden, 2003) . However, in human lung cancer cells, the IGF-II gene is more widely expressed than the IGF-I gene (Reeve et al., 1992) . Therefore, certain lung tumors may be associated with the re-expression of IGF-II, and IGF-II may serve as a risk factor for lung cancer. The link between IGF-II and lung cancer has been observed by several groups. IGF-II has been identified as the predominant IGF involved in the autocrine growth stimulation of human lung tumor cell lines (Quinn et al., 1996) . In addition, a majority of non-small cell lung cancers (NSCLCs) and squamous cell lung cancers have high levels of IGF-II and IGF-IR (Pavelic et al., 2002) . Cell culture experiments have also demonstrated that administration of exogenous IGF-II results in induced proliferation of small cell lung cancer (SCLC) cell lines (Nakanishi et al., 1988) . Moreover, pulmonary adenocarcinoma patients with a high percentage of IGF-II positive cells have a worse prognosis than patients with tumors containing low IGF-II staining (Takanami et al., 1996) .
The mitogenic and antiapoptotic actions of IGF-II are mediated by the type I insulin-like growth factor receptor (IGF-IR), insulin receptor (IR) and hybrid receptors that result from the dimerization of IGF-IR and IR hemireceptors. However, previous data indicate that the IGF-IR is the predominant pathway for the mitogenic activity of IGF-II with regard to human lung cancer cells (Rotsch et al., 1992; Reeve et al., 1993; Rubin and Baserga, 1995) . Lung cancer cells produce IGF-IR and IGF-II, stimulating proliferation in an autocrine fashion (Pavelic et al., 2002) . Inhibition of IGF-IR signaling pathways using a dominant-negative IGF-IR has been shown to suppress tumorigenecity, increasing A549 sensitivity to apoptosis (Jiang et al., 1999) . After ligand-dependent receptor autophosphorylation, the IGF-IR phosphorylates a series of adaptor proteins, including insulin receptor substrate-1 (IRS-1), to activated intracellular signaling including the phosphatidylinositol-3 kinase (PI-3 kinase) and p42/44 MAPK (Erk1/Erk2) (Rubin and Baserga, 1995; Baserga, 1999) . However, little is known about the activation of these pathways by IGF-II in lung cancer.
Our previous in vivo studies have demonstrated that overexpression of human IGF-II in lung epithelium of MMTV-IGF-II transgenic mice is sufficient to induce lung tumors. The presence of prosurfactant protein C, surfactant protein B and thyroid transcription factor 1 in these lung tumors, indicate that the tumors arose from type II alveolar cells or Clara cells, (Moorehead et al., 2003) . These two cell types, type II alveolar cells and Clara cells are believed to be the origin of human lung adenocarcinoma (Malkinson, 1991; Rehm et al., 1991) . Further examination of lung tumors from the IGF-II transgenic mice revealed high levels of phosphorylated cAMP response element binding protein (CREB), suggesting that the transformation of the lung is extremely sensitive to IGF-II overexpression and activation of CREB may represent a downstream event critical for the development of lung tumors.
CREB is a transcription factor that regulates various target genes in response to diverse stimulus, including peptides, hormones, neuronal activity and growth factors (Shaywitz and Greenberg, 1999) . CREB is a transcriptional activator when phosphorylated at the serine 133 phospho-acceptor site (Gonzalez et al., 1989) and a repressor of transcriptional activity in the hypophosphorylated state (Ofir et al., 1991; Hagiwara et al., 1992) . Although the biological implication of CREB is extensively studied in terminally differentiated tissues such as cerebrum (Ginty et al., 1993; Bourtchuladze et al., 1994) and retina (Yoshida et al., 1995; AlvarezLopez et al., 2004) , the involvement of CREB in tumor cell survival is not well documented.
To understand how IGF-II regulates CREB phosphorylation, several signaling molecules downstream of the IGF-IR were examined in the human lung adenocarcinoma cell lines A549 and NCI-H358. We showed that IGF-II-induced activation of CREB is mediated, at least in part, by the Erk5 pathway. Suppression of Erk signaling inhibited cell proliferation with little effect on apoptotic rate. The importance of CREB in maintaining a transformed phenotype was demonstrated by transfecting A549 and NCI-H358 cells with a dominantnegative CREB vector, KCREB. KCREB transfection significantly inhibited A549 and NCI-H358 colony formation in a soft agar assay. Overexpression of wildtype CREB in the normal human bronchial epithelial cell line, HBE135, resulted in a significant increase in the ability of these cells to form colonies in a soft agar assay. Therefore, our data indicate that CREB is a vital regulator of lung tumorigenesis and it can be activated by IGF-II via the Erk5 pathway.
Results

IGF-II stimulates CREB phosphorylation through the Erk pathway
Previous characterization of lung tumors in MMTV-IGF-II transgenic mice revealed that phosphorylation of the transcription factor CREB was a ubiquitous event and that CREB could be activated in human lung cancer cell lines in response to IGF-II administration (Moorehead et al., 2003) . These findings suggest that CREB activation could play a role in lung tumorigenesis. Therefore, we wanted to investigate the pathways regulating IGF-II-induced CREB phosphorylation. To identify the IGF-II-induced signaling pathways accountable for the mitogenic and antiapoptotic actions in these cells, specific inhibitors were investigated. Two key signaling molecules downstream of the IGF-IR were targeted: PI3-kinase (LY294002; Calbiochem, Mississaga, ON, Canada) and Erk1/Erk2 (U0126; Cell Signaling, Beverly, MA, USA). For each inhibitor, the levels of phosphorylated Erk1/Erk2 and Akt were examined by Western blotting. As U0126 can also inhibit activation of Erk5, the levels of phosphorylated Erk5 were also examined.
Administration of recombinant IGF-II (20 ng/ml) induced phosphorylation of Erk1/Erk2, Erk5, Akt, CREB and ATF1. Pre-incubation of A549 cells with U0126 (20 mM) completely inhibited IGF-II induced Erk1/Erk2 phosporylation at all time points examined in A549 cells (Figure 1a ). In addition, Erk5, CREB and ATF1 phosphorylations were greatly inhibited. As expected, the levels of phosphorylated Akt were not affected by this inhibitor. The PI3-kinase inhibitor LY294002 suppressed IGF-II-induced phosphorylation of Akt, with little or no effect on Erk1/Erk2, CREB or ATF1 phosphorylation (Figure 1a ). LY 294002 did not inhibit Erk5 phosphorylation, but may have altered the kinetics slightly. Therefore, U0126, but not LY294002, was capable of suppressing CREB phosphorylation, indicating that activation of Akt does not significantly contribute to the phosphorylation of CREB. Similar results were observed in NCI-H358 cells (data not shown).
To distinguish whether CREB phosphorylation was mediated by Erk1/2, Erk5 or both, A549 cells were preincubated with a peptide that blocks the activation of Erk1/2 by inhibiting MEK1 (Kelemen et al., 2002) . This anti-MEK1 peptide inhibited Erk1/2 phosphorylation in a dose-dependent manner but did not significantly impact the phosphorylation of Erk5, CREB or ATF1 (Figure 1b ). These findings suggest that Erk5, not Erk1/2, is the major upstream regulator of IGF-IIinduced CREB phosphorylation in A549 cells.
U0126 also inhibits cell survival and proliferation
We previously demonstrated that IGF-II enhanced cell survival in A549 and NCI-H358 cells (Moorehead et al., 2003) . To determine whether inhibition of Erk pathway activation also affects cell survival, an MTT assay was used. The effect of human recombinant IGF-II on cellular survival in A549 and NCI-H358 cell lines was previously demonstrated using an MTT assay; a 1.7-fold increase in survival at 20 ng/ml IGF-II was revealed (Moorehead et al., 2003) . Therefore, we utilized IGF-II at 20 ng/ml for our survival assays. As shown in Figure 2a , U0126 significantly inhibited A549 cell survival in the presence of IGF-II. DMSO controls at the concentrations used had no effect on cell survival (data not shown). A similar decrease in cell survival was observed in NCI-H358 cells (data not shown).
Having shown that administration of U0126 inhibited IGF-II-mediated survival in A549 cells, we then proceeded to examine whether increased survival resulted from increased proliferation or decreased apoptosis. Inhibition of Erk signaling in A549 cells significantly suppressed IGF-II-induced proliferation by 50-60% ( Figure 2b ). In contrast, there was only a very small, nonsignificant increase in the number of apoptotic cells following treatment with U0126 ( Figure 2b ).
CREB activation plays an important role in lung tumorigenesis
To further ascertain the biological role of CREB in lung cancer, A549 and NCI-H358 cells were transfected with a dominant negative version of CREB, KCREB. The pCMV-KCREB construct encodes a CREB protein with a mutation in the DNA binding domain. KCREB acts as a dominant-negative repressor of the wild-type CREB, blocking the ability of wild-type CREB to bind to CRE when present as a KCREB : CREB heterodimer. Soft agar assays, an indicator of anchorage-independent growth and thus tumorigenicity, were performed using KCREB-transfected lung tumor cells. Dominantnegative CREB expression resulted in an eightfold and 37-fold reduction in colony formation in A549 and NCI-H358 cells, respectively ( Figure 3 ).
IGF-II does not induce cell survival or CREB phosphorylation in normal bronchial epithelial cells
To determine whether normal lung epithelial cells respond to IGF-II in a manner similar to lung tumor cells, survival was assessed in the normal human bronchial epithelial cell line, HBE135, using an MTT assay. The concentration of IGF-II (20 mM) sufficient to induce an approximate twofold increase in cell survival in tumor cells had no effect on HBE135 cells (Figure 4a ). IGF-II had little or no effect on CREB phosphorylation or on the activation of Erk1/Erk2 or Akt pathways in HBE135 cells (Figure 4b ). Western blot analyses reveal that the levels of IGF-IR were lower in HBE135 cells compared to A549 and NCI-H358 cells. In contrast, HBE135 cells had higher levels of the IR than either A549 or NCI-H358 cells (Figure 4c -i).
CREB overexpression enhances tumorigenicity of normal bronchial epithelial cells
If CREB is a critical regulator of lung tumorigenesis, overexpression of CREB in normal lung epithelial cells should promote transformation. Therefore, HBE135 cells were stably transfected with a wild-type CREB construct driven by a CMV promoter. As expected, HBE135 rarely formed colonies under anchorageindependent conditions. However, transfection of CREB into HBE135 cells resulted in a significant increase in soft agar colony formation, indicating that CREB stimulated HBE135 cells to acquire a more transformed phenotype ( Figure 5 ).
Discussion
We have previously demonstrated that transformation of lung epithelial cells in transgenic mice overexpressing IGF-II was associated with hyperphosphorylation of CREB. In addition, administration of recombinant IGF-II to cultured human lung tumor cell lines enhanced cell survival and induced CREB phosphorylation (Moorehead et al., 2003) . In this manuscript, we extend these findings to determine the signaling pathways mediating the IGF-II-induced phosphorylation of CREB and further examine the role of CREB in cell transformation.
Binding of IGF-I or IGF-II to the IGF-IR results in the activation of four main signal transduction pathways; Erks, PI-3 kinase/Akt, p38 MAPK and JNK/ SAPK (Rubin and Baserga, 1995; Baserga, 1999) . The levels of phosphorylated p38 MAPK and JNK/SAPK were undetectable in A549 and NCI-H358 cells and thus were not investigated further in this study. To determine the relative importance of the Akt and Erk pathways in regulating IGF-II-induced CREB phosphorylation, selective signaling inhibitors were utilized. Western blot analysis confirmed that LY294002 inhibited the phosphorylation of Akt without impacting Erk1/2 phosphorylation. Similarly, U0126 abolished Erk1/2 phoshorylation with little or no effect on Akt phosphorylation. The levels of phosphorylated Erk5 were also examined, as studies have demonstrated that in addition to inhibiting Erk1/2 phosphorylation, U0126 can also suppress Erk5 phosphorylation by negatively regulating MEK5 activity. U0126, but not LY294002, suppressed IGF-II-induced Erk5 phosphorylation. The phosphorylation of CREB was inhibited by U0126 but not by LY294002 indicating that activation of the Erk pathway was the predominant mediator of CREB phosphorylation in response to IGF-II administration.
Investigation of the Erk pathway was further examined using a 13-amino-acid peptide that interferes with MEK1-mediated activation of Erk1/2 (Kelemen et al., 2002) . This peptide does not interfere with MEK5-mediated activation of Erk5. Preincubation of A549 cells with the Erk1/2 activation inhibitor peptide demonstrated a dose-dependent reduction of Erk1/2 phosphorylation. Interestingly, CREB phosphorylation (and ATF1 phosphorylation) was unaffected by this peptide even at a dose that completely abolished detectable phosphorylated Erk1/2. Erk5 phosphorylation was also not significantly affected by the Erk1/2 activation inhibitor peptide. Since Erk1, Erk2 and Erk5 are the only identified targets of U0126 to date, and U0126 but not the Erk1/2 activation inhibitor peptide inhibits CREB phosphorylation, it would appear that Erk5 is one of the predominant upstream activators of CREB phosphorylation in response to IGF-II administration.
ERK5 has previously been identified in lung cell lines including the Clara-like bronchiolar pulmonary adenocarcinoma cell line NCI-H441 and the murine alveolar epithelial type II cell line C10 (Reddy et al., 2002; Scapoli et al., 2004) . In addition, Erk5 can phosphorylate CREB in neurons (Watson et al., 2001 ) and can be activated by IGFs in endothelial cells (Liu et al., 2001) . Thus, each of the components starting with activation of the IGF-IR and ending with CREB phosphorylation has previously been demonstrated in separate experiments and in this study we demonstrate that CREB phosphorylation in response to IGF-II is mediated, at least in part, by Erk5 in lung tumor cells.
Unfortunately, there were no sufficient levels of phosphorylated p38 MAPK or JNK/SAPK in the A549 cells to examine effectively whether these pathways impact CREB phosphorylation. Therefore, our data indicate that Erk5 is a regulator of CREB phosporylation in A549, but other pathways may also contribute to CREB phosphorylation in response to IGF-II.
Erk5-mediated activation of CREB appears to play an important role in lung tumorigenesis, as administration of U0126 to either A459 or NCI-H358 cells significantly inhibited cell survival. As the MTT assay only provides an estimate of the cell number, it is impossible to use this assay to determine whether disruption of specific signaling pathways decreases cell proliferation, increases apoptosis, or both. In order to examine whether the decreased cell survival was attributed to increased apoptosis or decreased proliferation, specific immunohistochemical analyses were performed. We found that treatment with U0126 in the presence of IGF-II inhibited A549 cell proliferation compared to cells treated with IGF-II alone. In contrast, the percentage of cells undergoing apoptosis only increased slightly. We are confident that our apoptotic assay was capable of detecting changes in cell apoptosis, as treatment of the cells with either the p38 MAPK or JNK/SAPK inhibitor increased the percentage of A549 cells undergoing apoptosis to 88 and 83%, respectively (data not shown). Activation of p38 MAPK or JNK/ SAPK pathways has previously been shown to induce apoptosis (Petrich and Wang, 2004; Wada and Penninger, 2004) . It should be noted that inhibition of the Akt, p38 MAPK and JNK/SAPK pathways also reduced cell survival as determined by the MTT assay. However, U0126 was the most potent inhibitor of tumor cell proliferation. Therefore, although our data demonstrate that activation of CREB is an important regulator of lung tumor cell survival, other signaling pathways downstream of the IGF-IR can also negatively impact lung tumor cell survival.
Unfortunately, established, normal human type II alveolar cell and Clara cell lines do not exist, and thus it is difficult to compare our findings in A549 and NCI-H358 cells to normal lung cells. In an attempt to determine differences between lung tumor cells and normal lung cells, we utilized the normal human bronchial epithelial cell line HBE135. These cells are not truly normal, as they have been immortalized through retroviral transfection of the human papilloma virus E6E7 gene. When the effects of IGF-II on normal bronchial epithelial cells (HBE135) were examined, we found that IGF-II administration did not enhance HBE135 survival. Also, there was little or no induction of Erk1/Erk2, Akt or CREB phosphorylation after IGF-II treatment in HBE135 cells. Although direct comparisons between the HBE135 cells and A549 or NCI-H358 cells cannot be made, it is possible that the HBE135 cells respond differently to IGF-II administration than the tumor cells due to a lower level of IGF-IR expression. A549 and NCI-H358 cells both had considerably higher levels of IGF-IR and lower levels of the IR than HBE135 cells. The elevated IGF-IR levels on the tumor cells (A549 and NCI-H358) may be a result of transformation as many types of tumors have elevated IGF-IR levels compared to normal tissue (Rubin and Baserga, 1995; Surmacz et al., 1998; Baserga, 1999; Grothey et al., 1999; Pavelic et al., 1999; Rubini et al., 1999; Adams et al., 2000; Valentinis and Baserga, 2001) . Alternatively, different cell populations within the lung may have variable levels of IGF-IR expression. In alveolar epithelial cells and Clara cells, the cell types from which A549 and NCI-H358 cells were derived, respectively, IGF-IR expression may be higher than in bronchial epithelial cells. The hypothesis that IGF-IR levels are higher in alveolar epithelium or Clara cells compared to bronchial epithelial cells is consistent with our observations that tumors appeared to originate from type II alveolar or Clara cells, rather than bronchial epithelial cells, in our IGF-II-overexpressing transgenic mice (Moorehead et al., 2003) . Whether adult human bronchial epithelial cells contain lower levels of IGF-IR than alveolar epithelial or Clara cells remains unclear.
CREB is a member of the CREB/ATF-1/CREM transcription factor family. This transcription factor family mediates growth factor and calcium regulated gene expression by interacting with cAMP response element (CRE). CREB is found in almost all cells in species from Drosophila to humans and responds to signals from hormones, growth factors and neurotransmitters. CREB is a transcriptional activator when phosphorylated at the Ser133 phospho-acceptor site (Gonzalez et al., 1989) and a repressor of transcriptional activity in the hypo-phosphorylated state (Ofir et al., 1991; Hagiwara et al., 1992) . Phosphorylation on Serine 133 results in binding of CREB as homodimers or heterodimers with other members of the CREB/ATF superfamily to CRE in the promoter region of a number of genes involved in cell survival, glucose homeostasis and learning and memory (Shaywitz and Greenberg, 1999; Jean and Bar-Eli, 2000; Sung et al., 2001; Shankar and Sakamoto, 2004) . Following DNA binding, CREB interacts with CREB-binding protein (CBP), which in turn permits recruitment and stabilization of RNA polymerase II complex. Some specific examples of genes regulated by CREB are c-fos, bcl-2 and egr-1 (Ginty et al., 1993; Sakamoto et al., 1994; Dong et al., 1999) . Several of these genes have been implicated in tumorigenesis. The bcl-2 oncogene acts as an inhibitor of apoptosis by forming a dimer with the proapoptotic protein Bax, thereby blocking cytochrome c release from the mitochondria (Adams and Cory, 1998) . The c-fos and egr-1 genes play a central role in the nuclear response to stimulatory signals that regulate cell proliferation and differentiation (Arteaga and Holt, 1996; Khachigian and Collins, 1998; Yan et al., 2000; Jochum et al., 2001; Thiel and Cibelli, 2002) .
To determine whether CREB activation plays a causal role in lung tumorigenesis, CREB was constitutively overexpressed in normal bronchial epithelial cells. If CREB is a critical factor for IGF-II-induced cell survival, overexpression of CREB in normal cells should take on tumorigenetic characteristics in the absence of IGF-II. As seen in this study, CREB overexpression induced a notable increase in anchorage-independent colony growth, suggesting that IGF-II has some capacity to enhance tumorigenicity in these cells ( Figure 5 ). To further verify CREB involvement in tumor growth in lung adenocarcinoma cells, we also used a dominant-negative cDNA construct of CREB, KCREB, that had been mutated in the DNA binding domain. Overexpression of the KCREB mutant would be expected to yield proper heterodimerization with CRE-binding proteins, but prevent DNA binding and transcriptional activity. Dominant-negative experiments with KCREB have shown inhibition of tumor growth and metastasis in human melanoma cells, indicating that CREB may be a good target for lung tumorigenesis (Xie et al., 1997) . In this study, A549 and NCI-H358 tumorigenicity as a result of overexpression of KCREB was measured using an anchorage-independent growth assay. The KCREB-transfected cells displayed a significant decrease in anchorage-independent growth. These results indicate that, through transcriptional activity, CREB and its associated proteins play an important role in lung adenocarcinoma.
The importance of CREB has been demonstrated in a limited number of human tumors but not in lung cancer. CREB has been shown to be involved in leukemogenesis (Perissi et al., 1999; Shankar and Sakamoto, 2004) , human melanoma cell survival (Jean et al., 1998) and several endocrine tumors (Habener et al., 1989; Peri et al., 2002; Rosenberg et al., 2002a, b; Luciani et al., 2003) . Also, inhibition of Erk1/Erk2 and CREB phosphorylation can inhibit growth and induce apoptosis in cells derived from human fibrosarcoma (Rabelo et al., 2003) . In addition, antisense oligonucleotides directed against CREB induce death of human leukemia cells and bone marrow cells in patients with chronic myeloid leukemia (Saeki et al., 2001) . CREB, however, does appear to play a role in normal lung development. A percentage of CREB null mice are born but these offspring are cyanotic and die within 15 min from the time of birth from respiratory distress. Histological analysis of the lung revealed severe atelectasis and Northern analysis demonstrated reduced surfactant protein-D expression (Botas et al., 1998) .
Increased IGF-II levels are known to be associated with poor prognosis of human lung adenocarcinomas; however, the role of IGF-II in tumorigenesis is not well studied. Our findings suggest that IGF-II mediates proliferation of human lung alveolar type II and Clara cells primarily via activation of the Erk5 signaling pathway resulting in CREB phosphorylation. CREB appears to be a critical regulator of lung tumorigenesis as downregulation of CREB in lung tumor cells suppressed soft agar growth, while CREB overexpression in normal bronchial epithelial cells enhanced soft agar growth. We are currently generating transgenic mice to overexpress CREB in lung tissue to determine whether CREB overexpession induces lung tumors in vivo and to examine whether CREB represents a clinical marker of lung tumorigenesis and/or represents a therapeutic target for the treatment of human lung cancer.
Materials and methods
Cell culture
Human pulmonary adenocarcinoma cell lines A549 (Type II alveolar cell derived) and NCI-H358 (Clara cell derived) were generously provided by Dr Ming Tsau (Department of Pathology at the University Health Network/Ontario Cancer Institute, Toronto, ON, Canada). A549 and NCI-H358 cells were grown in RPMI 1640 medium supplemented with 5% fetal bovine serum (FBS) and 1% antibiotic. Normal human bronchial epithelial cells, HBE135, were grown in keratinocyte media (Invitrogen, Burlington, ON, Canada) supplemented with human recombinant epidermal growth factor, bovine pituitary extract and 1% antibiotic. All cells were maintained at 371C and 5% carbon dioxide.
Western blot analysis
Western blotting and stripping of the blots was performed as previously described (Moorehead et al., 2001) . Proteins were detected using the following antibodies; 1 : 1000 dilution of antiphospho-CREB (Ser133), antiphospho-Akt (Ser473), phospho-Erk1/Erk2 (Tyr202/Thr204) (Cell Signaling Technologies, Beverly, MA, USA), IGF-IR (R&D Systems Inc., Minneapolis, MN, USA) and IR (Santa Cruz Technologies, Santa Cruz, CA, USA) in 5% skim milk. Protein levels were detected using Western Lightning Chemiluminescence substrate (Perkin Elmer, Wellesley, MA, USA). Images were captured and quantified on a Fluorchem8800 gel documentation system (AlphaInnotech, San Leando, CA, USA). Equal loading of protein was verified using an anti-tubulin antibody (1 : 5000; Santa Cruz Technologies, Santa Cruz, CA, USA). U0126 (10 mM), LY294002 (10 mM) or Erk1/2 inhibitor peptide (various concentrations) (Calbiochem/EMD Biosciences, La Jolla, CA, USA) was added to the cells at least 15 min prior to the addition of 20 ng/ml recombinant IGF-II. Time points were determined from the time of IGF-II administration.
Immunofluorescence
Cells were plated onto sterile coverslips at a density of 5 Â 10 5 cells in fully supplemented keratinocyte media and allowed to adhere for approximately 4 h. Cells were then washed twice with PBS and fixed with 10% neutral-buffered formalin for an hour at room temperature. Coverslips with fixed cells were incubated overnight at 41C with antibodies specific for the IGFIR (1 : 50; R&D Systems Inc., Minneapolis, MN, USA) or the IR (1 : 50; Santa Cruz Technologies, Santa Cruz, CA, USA). FITC-conjugated antirabbit secondary antibody (1 : 100; Sigma, Oakville, ON, Canada) was used for detection and cells were counterstained with propidium iodide. Images were captured with an Olympus BX-61 fluorescent microscope.
Survival assay
The effects of IGF-II on human lung adenocarcinoma cell lines A549, and NCI-H358 and normal human bronchial epithelial cells HBE135 were measured by the colorimetric MTT assay. A549, NCI-H358 and HBE135 cell lines were plated in 96-well plates at a density of 3 Â 10 3 cells/well and allowed to adhere for approximately 4 h. Cells were then serum starved for 24 h prior to treatment. Cells were treated with IGF-II (20 ng/ml) and inhibitors (LY294002 and U0126) in a dose-dependent manner for 3 days. On the fourth day, cell growth was assessed through the conversion of tetrazolium salt (MTT) (Sigma, Oakville, ON, Canada) by viable cells to a purplish precipitate, which was then dissolved and quantified on a plate reader at 570 nm.
Apoptosis
Apoptosis in cultures of A549 and NCI-H358 cells was assessed in the presence and absence of signaling inhibitors using a DNA fragmentation assay, In Situ Cell Death Detection Kit, POD (Roche Diagnostics, Laval, QC, Canada). The TUNEL assay was performed as described by Roche Diagnostics. Cells were seeded in 6-well plates at 5 Â 10 5 cells/ well and allowed to adhere for 4 h in fully supplemented RPMI 1640 medium. Cells were serum starved for 24 h, and serumfree medium containing appropriate concentrations of IGF-II and inhibitor was added. Inhibitors (LY294002 (10 mM) and U0126 (10 mM)) were added 15 min prior to IGF-II (20 ng/ml) treatment for 18 and 24 h. Cells were then washed with PBS and fixed with 10% neutral-buffered formalin. Cells were permeabilized in 0.1% Triton X-100 (Sigma, Oakville, ON, Canada), washed with PBS and incubated with an FITCconjugated enzyme for 1 h. A propidium iodide counterstain was used to stain cell nuclei and cells were imaged using an Olympus BX-61 microscope and integrated morphometry software (Metamorph, Universal Imaging Corp., CA, USA).
Proliferation assay
A549 and NCI-H358 cells were seeded onto coverslips at a density of 5 Â 10 5 cells/well in a six-well plate. Cells were allowed to adhere to the coverslips in fully supplemented RPMI 1640 media. Cells were then serum starved for 24 h, and serum-free medium containing the appropriate inhibitor plus IGF-II (20 ng/ml) were added. Inhibitors LY294002 (10 mM) and U0126 (10 mM) were added 15 min prior to IGF-II and BrdU (10 mM). Cells were incubated with the appropriate treatment for 30, 60 and 120 min at 371C and 5% carbon dioxide. Coverslips were washed in PBS and fixed with formalin at room temperature for 1 h and stored at 41C. Cells were incubated with 2 N HCL for 30 min at room temperature, sodium borate (0.1 M; pH 7.0) for 5 min, washed with PBS and incubated with 0.2% sodium borohydride for 30 min at room temperature. Coverslips were then blocked with 5% BSA for 30 min at room temperature and the anti-BrdU antibody (Sigma, Oakville, ON, Canada) was added at a dilution of 1 : 1000 in 5% BSA. Following an overnight incubation at 41C, the coverslips were incubated with an FITC-conjugated antirabbit secondary antibody (Sigma, Oakville, ON, Canada) in 5% BSA (1 : 100) for 1 h. Cell nuclei were counterstained with propidium iodide and imaged using an Olympus BX-61 fluorescent microscope.
Creation of stable cell lines overexpressing CREB and KCREB
Vectors pCMV-CREB (wild-type CREB) and pCMV-KCREB (mutations in the DNA-binding domain) were purchased from BD Biosciences Clonetech. A549 and NCI-H358 cells were transfected with the pCMV-KCREB and HBE135 cells were transfected with pCMV-CREB vector (2 mg) using FuGENE 6 reagent (3 ml) (Roche Molecular Biochemicals, Indianapolis, IN, USA) in serum-free opti-mem media (Invitrogen, Burlington, ON, Canada). At 2 days after transfection cells were treated with G418 (500 mg/ml) (Sigma, Oakville, ON, Canada) in medium containing 10% FBS. Several surviving cell clones were picked and expanded in genetomycin-containing media for several weeks.
Soft agar assay
A549 and NCI-H358 cells transfected with pCMV-KCREB and HBE135 cells transfected with pCMV-CREB were cultured to 60-80% confluence. Cells were washed twice with PBS, incubated with trypsin-EDTA (Invitrogen, Burlington, ON, Canada) and counted. Base agar was made up of equal volumes of 1% agar noble (DIFCO Laboratories, Detroit, MI, USA) and full serum media. Top agar consisted of equal volumes of 0.7% agar noble and 5000 cells per 1.5 ml of media. Once the agar layer solidified, 2 ml of media was added to the top of the agar. Cell colonies were allowed to grow for 30 days, with media changes every 3 days. After 30 days, colonies were stained with 0.5 ml of 0.005% crystal violet for 1 h and imaged and counted using a Fluorchem 8800 imaging system and Alpha Ease FC software (Alpha Innotech, San Leandro, CA, USA).
Statistics
All values are presented as mean7s.e.m. Statistical significance was determined using a Student's t-test when two values were compared, or an ANOVA followed by a Dunnett's test if multiple treatments were compared to the same control value. Values were considered significant when Po0.05.
